文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

外照射放疗后前列腺癌的剂量反应与分次敏感性:随机试验荟萃分析

Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-15

该荟萃分析纳入13项随机试验共10184例前列腺癌患者,评估外照射放疗改变剂量/分次后的剂量反应与分次敏感性。剂量递增试验中bNED的剂量反应参数γ50为0.62(95%CI 0.37-0.87),分次试验估算α/β为1.2 Gy(95%CI 0.8-1.7)。未发现OS的剂量反应,bNED获益与OS改善无相关性。

要点

  • 中度大分次放疗数据与低α/β值一致,α/β为1.2 Gy(95%CI 0.8-1.7)。
  • 剂量递增试验显示bNED存在剂量反应,γ50为0.62(95%CI 0.37-0.87)。

核心结论

  • 中度大分次放疗报告的数据与低α/β值一致,且置信区间较窄。
  • 剂量递增试验证明bNED存在剂量反应。
  • 剂量递增至>80 Gy EQD2可能不改善bNED。
  • 未发现bNED获益与OS改善之间的相关性。

研究设计与样本

  • 通过PubMed检索截至2017年4月1日的随机试验。
  • 纳入任何风险前列腺癌患者及任何外照射放疗修改的研究。
  • 共识别13项随机试验,涉及10184例患者。
  • 收集bNED和OS的风险比作为结局比较。
  • 对剂量递增试验逐项估算bNED剂量反应曲线陡度,并行逆方差加权。

主要发现

  • 剂量递增试验中bNED的γ50为0.62(95%CI 0.37-0.87),考虑总治疗时间效应后为0.87(95%CI 0.53-1.21)。
  • 8项分次试验(7946例患者)估算α/β为1.2 Gy(95%CI 0.8-1.7),考虑总治疗时间效应后为2.7 Gy(95%CI 1.6-3.8)。
  • 未发现OS的剂量反应迹象,也未发现与bNED改善的相关性。

关键数值与推荐

  • bNED剂量反应陡度γ50为0.62(95%CI 0.37-0.87),不考虑总治疗时间效应。
  • 考虑总治疗时间效应(延长治疗时间损失0.31 Gy/d)时γ50为0.87(95%CI 0.53-1.21)。
  • 分次试验估算α/β为1.2 Gy(95%CI 0.8-1.7),考虑总治疗时间效应后为2.7 Gy(95%CI 1.6-3.8)。

临床怎么用

  • 前列腺癌外照射放疗可采用中度大分次方案,与低α/β值一致。
  • 剂量递增可改善bNED,但递增至>80 Gy EQD2可能不再改善bNED。
  • bNED获益未转化为OS改善,临床决策需综合考量。

局限性

  • 分析假设总治疗时间无效应,并另行假设延长治疗时间损失0.31 Gy/d。
  • 未发现bNED获益与OS改善的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Randomized trials of altered dose/fractionation for external beam radiation therapy are meta-analyzed with the aim of establishing the dose response and fractionation sensitivity. METHODS AND MATERIALS: Studies were identified through PubMed through April 1, 2017. Studies of any-risk prostate cancer patients and any modification of external beam radiation therapy were included. The outcomes and comparisons collected were hazard ratios for biochemical no evidence of disease (bNED) and overall survival (OS). Trial-by-trial estimates of the steepness of the dose-response curve for bNED were performed for dose-escalation trials, followed by inverse variance weighting. The steepness was used to extract estimates of α/β, which were subsequently synthesized. Both analyses were performed assuming no effect of overall treatment time and were repeated assuming a loss of 0.31 Gy/d for a protracted treatment time. Finally, all trials were included in the analyses of the dose response for fractionation-corrected doses. This analysis was repeated for OS. Finally, the per-trial effect on OS was compared to the effect on bNED. RESULTS: We identified 13 randomized trials involving 10,184 patients. The dose response for bNED from dose-escalation trials was γ50 = 0.62 (95% confidence interval [CI] 0.37-0.87) and γ50 = 0.87 (95% CI 0.53-1.21) without and with the overall treatment time effect, respectively. The corresponding estimates of α/β from 8 fractionation trials (7946 patients) were 1.2 Gy (95% CI 0.8-1.7) and 2.7 Gy (95% CI 1.6-3.8). The heterogeneity in the data can be explained by the shallower dose response for bNED in trials with effective doses in the experimental arm >80 Gy equivalent dose in 2-Gy fractions (EQD2) (P = .04). No indication was found of a dose response for OS or a correlation with improvement in bNED. CONCLUSIONS: The reported data of moderate hypofractionation are consistent with a low α/β value with narrow CIs. Dose-escalation trials have demonstrated a dose response for bNED. Escalating doses to >80 Gy EQD2 might not improve bNED. A correlation between benefit in bNED and OS was not found.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vogelius IR, Bentzen SM. Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. Int J Radiat Oncol Biol Phys. 2017. PMID: 29485063. doi:10.1016/j.ijrobp.2017.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。